NEXGEL signs $35M deal to buy Celularity's biomaterial portfolio; expects revenue to triple to ~$35M

NEXGEL, INC.

Consideration up to $35M: $15M upfront plus $20M in milestone payments tied to net sales.
Deal expected to triple annual revenue to ~$35M and make NEXGEL immediately profitable upon closing.
Acquisition includes 6 commercial-stage regenerative products with existing reimbursement, plus 3 planned 510(k) filings through 2028.
Experienced commercial and scientific team from Celularity is expected to join NEXGEL, expanding sales reach.
NEXGEL also disclosed discussions for a $100M equity line of credit facility with a third-party investor.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

NEXGEL, INC. entered into Agreement with Celularity, Inc. valued at up to $35.0 million in cash, subject to certain adjustments, which will include (i) a $15.0 million (effective 2026-03-06).

Action: entry
Agreement: asset purchase
Counterparty: Celularity, Inc.
Value: up to $35.0 million in cash, subject to certain adjustments, which will include (i) a $15.0 million
Effective: 2026-03-06

Exact text from the filing

On March 6, 2026, NexGel, Inc., a Delaware corporation (the “ Company ”), entered into an Asset Purchase and Exclusive License Agreement (the “ Agreement ”) with Celularity, Inc., a Delaware corporation (the “ Licensor ”), whereby the Licensor granted to the Company an exclusive license to its commercial-stage biomaterials portfolio and certain development-stage programs as more fully described in the Agreement and the Licensor agreed to sell to the Company assets related to the portfolio (collectively, the “ Business ”). Consideration for the Business will consist of up to $35.0 million in cash, subject to certain adjustments, which will include (i) a $15.0 million upfront payment and (ii) an additional $20.0 million in potential milestone payments based on net sales targets related to the Business.

View on SEC.gov

317 material agreements filed in the last 30 days. Browse all material agreements →

NEXGEL, INC. filing history →

Source: SEC EDGAR

accession 0001493152-26-009474

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.